Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages||18 Years and Over|
- - Primary ductal or lobular breast cancer, non-small cell lung cancer, or malignant melanoma.
- - Type I or Type II LM with a "confirmed" or "probable" diagnosis according to EANO-ESMO guidelines 2017.
- - Life expectancy more than 2 months, as judged by the Investigator.
- - ECOG Performance status 0, 1, or 2.
- - Acceptable hematological status and liver and kidney function.
- - Written informed consent obtained in accordance with local regulations.
- - Presence of an intracerebroventricular access device before first dosing.
- - Obstructive or symptomatic communicating hydrocephalus.
- - Progressive systemic (extra-leptomeningeal) disease.
- - Uncontrolled life-threatening infection.
- - Ventriculo-peritoneal shunts without programmable valves.
- - Received craniospinal irradiation (for intraparenchymal or dural metastases) or intrathecal cytotoxic anti-cancer therapy less than 3 weeks prior to first dose of 177Lu-DTPA-omburtamab.
- - Severe non-hematologic organ toxicity; specifically, any renal, cardiac, hepatic, pulmonary, or gastrointestinal system toxicity Grade 3 or above prior to enrolment.
- - Grade 4 nervous system disorder.
- - Unacceptable coagulation function prior to first dosing defined as INR Grade 2 or above.
- - Female of childbearing potential, who are pregnant, breast-feeding, intend to become pregnant, or are not using highly effective contraceptive methods or male who is not using highly effective contraceptive method.
- - Other significant disease or condition that in the investigator's opinion would exclude the patient from the trial.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
|Phase 1/Phase 2|
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Principal Investigator Affiliation||N/A|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
|Countries||United Kingdom, United States|
The disease, disorder, syndrome, illness, or injury that is being studied.
|Leptomeningeal Metastasis, Solid Tumor, Adult|
Part 1 is a dose-escalation phase with a 3+3 sequential-group design in which patients will receive a dosimetry dose followed by maximum of five 5-week cycles of treatment doses of intracerebroventricular 177Lu-DTPA-omburtamab. Part 2 is a cohort-expansion phase in which patients will receive a treatment at the recommended dose determined in Part 1, until confirmed LM progression, unacceptable toxicity, or for maximum of 5 cycles, whichever comes first; however, the total number of cycles will be determined based upon data from Part 1 (e.g., the dosimetry data) to minimize the risk of radiation necrosis and decreased neurological function End of treatment will take place within 5 weeks after the last cycle and thereafter the patients will be enter the follow-up period. The patients will be followed for up until one year after first dose (Part 1) and 2 years after first dose (Part 2).
Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to five cycles.
Biological: - radiolabeled DPTA-omburtamab
Biological, radiolabeled DPTA-omburtamab
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Cedars-Sinai Medical Center
Los Angeles, California, 90048
Baltimore, Maryland, 21287
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Duke Cancer Center
Durham, North Carolina, 27710
M.D. Anderson Cancer Center
Houston, Texas, 77030
The University of Washington
Seattle, Washington, 98109
The Christie Hospital NHS Foundation Trust
The Royal Marsden Hospital